Robust integration of external control data in randomized trials
Abstract
One approach for increasing the efficiency of randomized trials is the use of "external controls" -- individuals who received the control treatment studied in the trial during routine practice or in prior experimental studies. Existing external control methods, however, can be biased if the populations underlying the trial and the external control data are not exchangeable. Here, we characterize a randomization-aware class of treatment effect estimators in the population underlying the trial that remain consistent and asymptotically normal when using external control data, even when exchangeability does not hold. We consider two members of this class of estimators: the well-known augmented inverse probability weighting trial-only estimator, which is the efficient estimator when only trial data are used; and a potentially more efficient member of the class when exchangeability holds and external control data are available, which we refer to as the optimized randomization-aware estimator. To achieve robust integration of external control data in trial analyses, we then propose a combined estimator based on the efficient trial-only estimator and the optimized randomization-aware estimator. We show that the combined estimator is consistent and no less efficient than the most efficient of the two component estimators, whether the exchangeability assumption holds or not. We examine the estimators' performance in simulations and we illustrate their use with data from two trials of…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis
- Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials
- Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
- Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta‐analysis, and network meta‐analysis of randomized trials with 94,283 participants
- Screen time increases overweight and obesity risk among adolescents: a systematic review and dose-response meta-analysis
- Exposure to WHO AWaRe antibiotics and isolation of multi-drug resistant bacteria: a systematic review and meta-analysis
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.